ATE383170T1 - Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c - Google Patents
Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis cInfo
- Publication number
- ATE383170T1 ATE383170T1 AT02759107T AT02759107T ATE383170T1 AT E383170 T1 ATE383170 T1 AT E383170T1 AT 02759107 T AT02759107 T AT 02759107T AT 02759107 T AT02759107 T AT 02759107T AT E383170 T1 ATE383170 T1 AT E383170T1
- Authority
- AT
- Austria
- Prior art keywords
- infection
- cell
- inhibit
- hcv
- hcv infection
- Prior art date
Links
- 102100040843 C-type lectin domain family 4 member M Human genes 0.000 title abstract 3
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 title abstract 3
- 101000749311 Homo sapiens C-type lectin domain family 4 member M Proteins 0.000 title abstract 3
- 208000010710 hepatitis C virus infection Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 14
- 150000001875 compounds Chemical class 0.000 abstract 6
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 101710121417 Envelope glycoprotein Proteins 0.000 abstract 2
- 102100021696 Syncytin-1 Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 abstract 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 abstract 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 abstract 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/891,894 US20030013081A1 (en) | 2001-06-26 | 2001-06-26 | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE383170T1 true ATE383170T1 (de) | 2008-01-15 |
Family
ID=25399013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02759107T ATE383170T1 (de) | 2001-06-26 | 2002-06-26 | Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030013081A1 (de) |
| EP (2) | EP1946770A1 (de) |
| JP (1) | JP2005521628A (de) |
| AT (1) | ATE383170T1 (de) |
| CA (1) | CA2452049A1 (de) |
| DE (1) | DE60224541T2 (de) |
| ES (1) | ES2296985T3 (de) |
| WO (1) | WO2003000024A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431990A1 (en) * | 2000-12-21 | 2002-06-27 | Stichting Katholieke Universiteit | Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| US7022323B2 (en) | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| WO2004026326A2 (en) * | 2002-09-20 | 2004-04-01 | Stichting Katholieke Universiteit | Antigen uptake receptor for candida albicans on dendritic cells |
| ES2527414T3 (es) * | 2003-03-04 | 2015-01-23 | Alexion Pharmaceuticals, Inc. | Método para el tratamiento de una enfermedad autoinmune mediante la inducción de la presentación de antígeno mediante células presentadoras de antígeno que inducen tolerancia |
| US20050281828A1 (en) * | 2003-03-04 | 2005-12-22 | Bowdish Katherine S | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
| CN113150076B (zh) * | 2021-03-03 | 2022-05-31 | 天津医科大学 | 环五肽的合成方法及其在抗丙肝药物中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3751863T2 (de) | 1986-05-20 | 1996-12-12 | Gen Hospital Corp | Bestimmung der Insulin Expression |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| NZ243908A (en) | 1991-08-16 | 1994-12-22 | Beth Israel Hospital Assn | Mutant l3t4 protein which facilitates hiv infection; transgenic mouse |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US5912411A (en) | 1993-06-14 | 1999-06-15 | University Of Heidelberg | Mice transgenic for a tetracycline-inducible transcriptional activator |
| CA2163229C (en) | 1994-03-18 | 2000-03-14 | Shinobu Abe | Method for examining neurovirulence of polio virus |
| EP0690452A3 (de) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Elektrisch löschbarer Speicher und Löschverfahren |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| US6018098A (en) | 1995-06-16 | 2000-01-25 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| US5894078A (en) | 1996-02-26 | 1999-04-13 | Advanced Bioconcept, Inc. | Transgenic mouse expressing C-100 app |
| US6025539A (en) | 1996-04-09 | 2000-02-15 | Mayo Foundation For Medical Education And Research | IL-5 transgenic mouse |
| US5981829A (en) | 1996-05-08 | 1999-11-09 | Uab Research Foundation | ΔNur77 transgenic mouse |
| US5981830A (en) | 1997-05-30 | 1999-11-09 | Schering Aktiengesellschaft | Knockout mice and their progeny with a disrupted hepsin gene |
| DE69841322D1 (de) | 1997-10-06 | 2010-01-07 | Novartis Vaccines & Diagnostic | Hepatitis c rezeptorprotein cd81 |
| EP1046651A1 (de) | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Zusammensetzungen und Verfahren zur Modulierung des interaktion zwischen dendritischer und T-zellen |
-
2001
- 2001-06-26 US US09/891,894 patent/US20030013081A1/en not_active Abandoned
-
2002
- 2002-06-26 JP JP2003506480A patent/JP2005521628A/ja active Pending
- 2002-06-26 EP EP08000261A patent/EP1946770A1/de not_active Withdrawn
- 2002-06-26 CA CA002452049A patent/CA2452049A1/en not_active Abandoned
- 2002-06-26 DE DE60224541T patent/DE60224541T2/de not_active Expired - Fee Related
- 2002-06-26 AT AT02759107T patent/ATE383170T1/de not_active IP Right Cessation
- 2002-06-26 WO PCT/US2002/020875 patent/WO2003000024A2/en active IP Right Grant
- 2002-06-26 EP EP02759107A patent/EP1411980B1/de not_active Expired - Lifetime
- 2002-06-26 ES ES02759107T patent/ES2296985T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003000024A2 (en) | 2003-01-03 |
| CA2452049A1 (en) | 2003-01-03 |
| ES2296985T3 (es) | 2008-05-01 |
| EP1411980A2 (de) | 2004-04-28 |
| DE60224541T2 (de) | 2008-12-24 |
| EP1411980A4 (de) | 2005-06-29 |
| US20030013081A1 (en) | 2003-01-16 |
| DE60224541D1 (de) | 2008-02-21 |
| JP2005521628A (ja) | 2005-07-21 |
| EP1946770A1 (de) | 2008-07-23 |
| WO2003000024A3 (en) | 2003-07-31 |
| EP1411980B1 (de) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE552340T1 (de) | Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismitteln | |
| EP2361913A8 (de) | Antiinfektiöse Mittel | |
| EA200300023A1 (ru) | 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ | |
| DE69435155D1 (de) | Zusuammensetzungen zur Behandlung von Krebs mittels Viren | |
| DE69434931D1 (de) | Methode zur selektiven inaktivierung der viralen replication | |
| CO5580797A2 (es) | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos | |
| DK0637342T3 (da) | Fremgangsmåde til typebestemmelse af HCV-isolater | |
| DE69934104D1 (de) | Inhibitoren von serin proteasen, insbesondere von hepatitis c virus ns3 protease | |
| CA2096159A1 (en) | Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates | |
| DK0713495T3 (da) | Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner | |
| WO2005000308A3 (en) | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c | |
| WO2002055025A3 (en) | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection | |
| ATE298889T1 (de) | Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung | |
| DE69821376D1 (de) | Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht | |
| DE60224541D1 (de) | Verwendung von dc-sign und dc-signr zur hemmung einer virusinfektion mit hepatitis c | |
| ATE309540T1 (de) | Analytisches verfahren unter verwendung von multipelviren-markierung | |
| DE69704180D1 (de) | Antivirusverbindungen | |
| ATE198070T1 (de) | Antivirusverbindungen | |
| DE69705582D1 (de) | Antivirusverbindungen | |
| ATE491952T1 (de) | Screening auf inhibitoren des eindringens von hepatitis-c-virus | |
| WO2003053332A3 (en) | Composition and method for treating viral infection | |
| DE69704229D1 (de) | Antivirusverbindungen | |
| WO2005062949A3 (en) | Method for treating hepatitis virus infection | |
| WO2003093431A3 (en) | Ablated slam-dependent entry | |
| DE60202619D1 (de) | Phosphorverbindungen als stabilisatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |